AJMC - The American Journal of Managed Care

The cancer drug shortage has been a critical issue, with significant impacts on patient care and clinical trials. Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network® (NCCN®), highlights the primary causes, including manufacturing issues, supply chain disruptions, and regulatory delays. Watch here! #CancerCare #DrugShortage #Oncology #ClinicalTrials #NCCN #Pharmaceuticals

In this #PeerExchange series, experts explore potential treatment advancements in paroxysmal nocturnal hemoglobinuria, underscoring the financial considerations of treatment. Watch the series now! https://bit.ly/3KyCWFr

This #AJMCInsights video series, featuring Justin Oldham, MD, MS, explores the unmet needs and future treatments for Idiopathic Pulmonary Fibrosis (IPF). Learn about the current standard of care, disease progression, management challenges, and the unmet needs in IPF treatment. Watch now: https://bit.ly/45Rwov9. #IPF

A new study reveals that former smokers using e-cigarettes face a higher risk of lung cancer and are less likely to adhere to recommended lung cancer screenings. The analysis highlights that only 26.7% of eligible individuals had undergone lung cancer screening (LCS), with a mere 14.6% up-to-date on testing. The study underscores the persistent misconceptions around e-cigarettes, which, despite being perceived as less harmful, contain carcinogens and cause similar gene deregulations as traditional cigarettes. #LungCancer #eCigarettes #PublicHealth #CancerPrevention #Screening

New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare

🎆 Happy Fourth of July from AJMC! 🎆 Wishing everyone a safe and joyful Independence Day! #FourthOfJuly #AJMC #CelebrateFreedom

New Guidelines Series! William Gradishar, MD, shares advances in breast cancer management, with insights on the growing role of CDK4/6 inhibitors, updates to NCCN guidelines, and anticipated research findings at ASCO 2024. Explore the series here: https://bit.ly/3ztL2wM #ASCO #ManagedCare #BreastCancerResearch

A recent study reveals differing outcomes in the cost-effectiveness of sotorasib compared with docetaxel as a second-line treatment for non–small cell lung cancer (NSCLC) with the KRAS G12C mutation in the US and China. The study assessed total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) using data from the 2022 willingness-to-pay thresholds: $12,374.81 to $37,124.42 for China and $76,348 to $229,044 for the US. In the US, sotorasib demonstrated cost-effectiveness with an ICER of $15,976.50/QALY. However, in China, the ICER was significantly higher at $102,701.84, exceeding the country's GDP threshold and indicating no economic advantage for sotorasib in this context. #Pharmacoeconomics #KRASInhibitors #NSCLC #CostEffectiveness #Sotorasib #Docetaxel

Register today for this free population health-focused event!

During the 2024 Community Oncology Conference, Shawn Tuma recorded an interview with the AJMC - The American Journal of Managed Care. Watch now to learn common data breach causes in the health care industry and how to reduce risk. https://lnkd.in/g-ivxRhm